- Increased 2019 revenue guidance to a range of 23% to 25% growth
- Acquisition of Orthex expands coverage from 60% to 80% of addressable trauma and deformity market and expands existing surgeon base
- Trauma growth partially driven by continued uptake of PNP Femur intramedullary nail system, launched in June 2018
- Increased summer volume of elective deformity surgeries offset a seasonal slowdown in 1Q
- Set deployments year to date are in the $12MM range, on pace for between $15MM and $17MM for the full year
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
2Q19 | 2Q18 | $ Chg | % Chg | |
Spine | $5.9 | $4.9 | $1.0 | 19.8% |
Trauma | $11.9 | $9.9 | $2.0 | 20.6% |
Sports Medicine | $0.4 | $0.3 | $0.1 | 39.7% |
Total | $18.2 | $15.1 | $3.1 | 20.7% |
1H19 | 1H18 | $ Chg | % Chg | |
Spine | $10.1 | $7.6 | $2.5 | 33.5% |
Trauma | $21.9 | $19.0 | $2.9 | 15.4% |
Sports Medicine | $0.8 | $0.6 | $0.2 | 36.6% |
Total | $32.9 | $27.2 | $5.7 | 20.9% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
2Q19 | 2Q18 | $ Chg | % Chg | |
US | $13.8 | $11.5 | $2.4 | 20.9% |
Ex-US | $4.4 | $3.6 | $0.7 | 20.3% |
Total | $18.2 | $15.1 | $3.1 | 20.7% |
Net Earnings Data
Net earnings, inclusive of all revenue, are as follows.
Amt | % of Sales | |
Sales | $18.2 | |
Cost of Sales | -$4.6 | 25.2% |
General and Admin | -$6.6 | 36.1% |
Selling and Marketing | -$7.6 | 41.8% |
R & D | -$1.2 | 6.8% |
Other | -$0.8 | 4.5% |
Net Earnings | -$2.6 | -14.4% |
Source: OrthoPediatrics
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Increased 2019 revenue guidance to a range of 23% to 25% growth
Acquisition of Orthex expands coverage from 60% to 80% of addressable trauma and deformity market and expands existing surgeon base
Trauma growth partially driven by continued uptake of PNP Femur intramedullary nail system, launched in June 2018
Increased...
- Increased 2019 revenue guidance to a range of 23% to 25% growth
- Acquisition of Orthex expands coverage from 60% to 80% of addressable trauma and deformity market and expands existing surgeon base
- Trauma growth partially driven by continued uptake of PNP Femur intramedullary nail system, launched in June 2018
- Increased summer volume of elective deformity surgeries offset a seasonal slowdown in 1Q
- Set deployments year to date are in the $12MM range, on pace for between $15MM and $17MM for the full year
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
2Q19 | 2Q18 | $ Chg | % Chg | |
Spine | $5.9 | $4.9 | $1.0 | 19.8% |
Trauma | $11.9 | $9.9 | $2.0 | 20.6% |
Sports Medicine | $0.4 | $0.3 | $0.1 | 39.7% |
Total | $18.2 | $15.1 | $3.1 | 20.7% |
1H19 | 1H18 | $ Chg | % Chg | |
Spine | $10.1 | $7.6 | $2.5 | 33.5% |
Trauma | $21.9 | $19.0 | $2.9 | 15.4% |
Sports Medicine | $0.8 | $0.6 | $0.2 | 36.6% |
Total | $32.9 | $27.2 | $5.7 | 20.9% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
2Q19 | 2Q18 | $ Chg | % Chg | |
US | $13.8 | $11.5 | $2.4 | 20.9% |
Ex-US | $4.4 | $3.6 | $0.7 | 20.3% |
Total | $18.2 | $15.1 | $3.1 | 20.7% |
Net Earnings Data
Net earnings, inclusive of all revenue, are as follows.
Amt | % of Sales | |
Sales | $18.2 | |
Cost of Sales | -$4.6 | 25.2% |
General and Admin | -$6.6 | 36.1% |
Selling and Marketing | -$7.6 | 41.8% |
R & D | -$1.2 | 6.8% |
Other | -$0.8 | 4.5% |
Net Earnings | -$2.6 | -14.4% |
Source: OrthoPediatrics
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.